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Bridging the communicable disease gap: Identifying,
treating and counseling high-risk inmates
Recent outbreaks of communicable diseases in
correctional settings have underscored the
importance of identifying communicable dis-
eases, educating inmates and staff, and treat-
ing where appropriate. In June 2001, an out-
break of HBV was reported in a state correc-
tional facility in Georgia (1). In November 2000,
the CDC reported an outbreak of TB in a state
correctional facility in South Carolina (2).
Concurrent syphilis outbreaks were identified in
three Alabama men’s state prisons in 1999 (3).
These events all point to an important gap
between awareness of infection (diagnosis)
and medical intervention in correctional set-
tings. This article describes the communicable
disease gap in correctional settings, and
addresses means of bridging that gap.
THE NEED TO KNOW
Lack of information about an inmate’s diagnosis
of HBV, TB, STD, and/or HIV may be due to the
inmate’s failure to provide this information,
unwillingness to be screened or inability to
access screening for these diseases, or the fail-
ure of routine hepatitis, TB, STD and HIV
screening protocols to detect communicable dis-
ease. Denial, fear of illness and concern about
confidentiality are major deterrents for inmates.
Concern about the cost of treatment may also
contribute to delays in diagnosis. Furthermore,
current guidelines for treating the disease may
advise delaying treatment until medically neces-
sary, diminishing the patient’s and providers’
sense of urgency about obtaining a diagnosis.
While some individuals may not need active
treatment under existing HIV and HCV guide-
lines, they are still likely to benefit from educa-
tion about their medical condition and the risk of
transmission to their families and communities
after release from incarceration. Furthermore, as
illustrated by outbreaks of communicable dis-
eases in correctional settings, inmates who have
communicable diseases sometimes continue to
participate in risky activities while incarcerated.
Diagnosis and appropriate medical intervention
may reduce the risk of communicable disease
transmission to other inmates and correctional
staff.
PREVALENCE OF COMMUNICA-
BLE DISEASES IN PRISON
According to the National Commission on
Correctional Healthcare’s "Health Status of
Soon-to-be-Released Inmates" project, the
diseases that are particularly prevalent in
prisons are HBV, HCV, HIV, sexually transmitted
diseases (STDs), including syphilis, chlamydia
and gonorrhea, and airborne diseases such as
TB (4,5,6). A summary of this report’s findings is
provided in the next four paragraphs.
HIV: 98,000 to 148,000 soon-to-be-released
inmates were infected with HIV at the time the
study was carried out (1998). This number
represents 12% to 18% of the total infected
population in the US. HIV infection is more
prevalent among incarcerated women than
incarcerated men, however the total number of
infected women is small (due to lower overall
numbers   of incarcerated women). (See Figure
1 and Table 1.)
STDs: Syphilis infection is highly prevalent in
correctional settings: in 1999 it was estimated
that 558,000 inmates were infected with syphilis
(RPR+) compared to 186,000 inmates infected
with chlamydia and 77,500 inmates infected with
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gonorrhea. In a 1999 study in New York City
it was found that although the rate of syphilis
infection among the general population had
reached a record low, prevalence among
incarcerated women was 25% (7). These
high numbers for STD infection are not
reserved for adult inmates: a study recently
conducted at two juvenile detention facilities
in Texas found that 22.2% of female and
8.7% of male participants were infected with
chlamydia (8).
TB: Active tuberculosis disease (TB) was
detected in 12,000 US inmates in 1999,
which accounts for 35% of total cases of TB
disease in the US. This TB case rate was
more than 50 times that of non-incarcerated
individuals (9). Active screening and appro-
priate medical intervention can have a dra-
matic effect on the incidence of TB in cor-
rectional settings, as demonstrated by the
significant decline of TB cases, from
225/100,000 to 26/100,000, in the New York
State Department of Corrections over the
past decade (10). In other settings, factors
such as failure to identify active TB and to
adequately treat latent TB infection (LTBI) in
inmate populations, difficulties obtaining
previous TB treatment records and lack of
continuity of care between institutions may
contribute to ongoing outbreaks of TB such
as the one recorded in Broad River, South
Carolina, last year.
Hepatitis: In terms of sheer numbers, the
two diseases that most disproportionately
affect inmate populations are hepatitis B
(HBV) and hepatitis C (HCV). In 1999 it was
estimated that 155,000 inmates being
released were infected with HBV. Up to 1.25
million inmates being released were esti-
mated to be infected with HCV. (See Table
1.)
RISKY BEHAVIOR IN 
CORRECTIONAL SETTINGS
Very little information is available about the
transmission of communicable diseases
inside US prisons and jails. Studies per-
formed outside of the United States have
demonstrated that inmates participate in a
number of high risk behaviors while incar-
cerated, including intravenous drug use
(IDU), which is the risk behavior that con-
tributes most to new HIV, HBV and HCV
infections. In a study conducted in England,
for instance, 58% of IDU inmates admitted
to injecting drugs while incarcerated, and
73% of those injecting in prison shared nee-
dles (11). A study in Canada also found that
the overwhelming risk association for HIV
and HCV was IDU, either inside or outside
prison (12). Two Australian studies have
found proof of both HCV and HIV transmis-
sion occurring within prison walls. It was
determined that IDU was the probable
cause for inmates contracting HIV and HCV,
while lacerations from barbers’ shears and
physical assault were the likely means of
HCV infection in other cases (13,14). It is
unknown, however, whether conditions in
British, Canadian and Australian institutions
compare to conditions in US facilities.
Other factors that may contribute to the
transmission of blood-borne, sexually trans-
mitted and airborne diseases in prisons and
jails include overcrowding, poor or delayed
access to healthcare and treatment, recidi-
vism and frequent transfers from one prison
to another (15). Some correctional institu-
tions have a policy of segregating HIV+ pris-
oners from seronegative inmates. While this
practice may have some benefits, including
being able to manage HIV+ prisoners’
healthcare more efficiently, it also concen-
trates individuals who are at higher risk of
opportunistic infections and disease. In
1999/2000, for instance, the CDC deter-
mined that segregation and concentration of
HIV+ inmates in one dormitory had con-
tributed to the outbreak of TB in a state cor-
rectional facility in South Carolina (2).
COMMUNICABLE DISEASE
FLAGS
Risky behaviors can be associated with
infection by more than one communicable
disease. For instance, acquiring an STD is
linked to unprotected sexual contact, which
should point to the associated risk of HIV
infection. In the same way, it is highly prob-
able that an inmate who is being treated for
IDU has been exposed to unsafe sex (trad-
ing sex for drugs or money, for instance),
meaning possible exposure not only to
blood-borne viruses like HBV and HCV, but
also to HIV and other STDs.
Identifying communicable disease "flags"
that signal the need to institute a screening
protocol is one way to reduce disease trans-
mission and improve patient education.
Every medical encounter can be viewed as
an opportunity to pick up on these signals,
allowing providers to intervene with appro-
priate medical intervention and/or education
(see HEPPigram page 6).
If limited resources for communicable dis-
ease screening are available, histories of
high risk behavior and some laboratory tests
can be used to identify higher-risk individu-
als, and testing can be confined to those
determined to have the most at-risk profile
(see HEPPigram). Childhood sexual abuse
and sex work have both been associated
with high risk of HIV infection, for instance
(16). Screening for these two "flags", along
with other indicators, can decrease the num-
ber of potential HIV test candidates.
BENEFICIAL STRATEGIES
HIV: The benefits of diagnosing and treating
are multiple. Routine recommendations for
HIV testing by primary health care providers
has been shown to improve the incidence of
requested testing, the identification of infect-
ed individuals and earlier diagnosis of infec-
tion, leading to earlier entry into care (17).
Inmates who are eligible for treatment may
experience fewer opportunistic infections
(18), fewer hospitalizations (19) and may be
less likely to transmit HIV if still participating
in HIV risk behavior (20).
HCV: HCV treatment guidelines for correc-
tional facilities will be published by the CDC
in late 2001 or early 2002. Because of the
prevalence of HCV infection among inmates
and the lack of official treatment protocols
guiding HCV treatment in corrections,
emphasis has shifted to identifying infected
individuals and providing education about
means of limiting further spread of HCV. As
Dr. Robert Greifinger, MD, recently said: "It’s
almost distracting to talk about treatment.
The much larger issue is prevention (21). "It
is hoped that education about HCV may
help motivate HCV-infected individuals to
take precautions against transmitting HCV
in communities to which they return, and to
seek appropriate HCV treatment in the com-
munity if it they are unable to participate in
HCV treatment while incarcerated.
HBV: The CDC has recommended that all
adults at risk of HBV infection be vaccinated
(inmates and staff in correctional institutions
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Table 1. Hepatitis and HIV Disease Prevalence ***
HCV
3.9 million
35,000
8,000
640,000-
1.4 million
16-33%
Chronic Infections
New Infections Per Year
Deaths Per Year
Number of Infected Inmates Released
Representing __% of US Population with Disease
HBV
1.2 million
120,000
5,000
155,000**
12.4-15.5%
HIV
0.8 million
40,000
18,000
98,000-
145,000
12-18%
Hepatitis and HIV Prevalence in US Populations
Hepatitis and HIV Prevalence Among Inmates Released From Prisons & Jails*
* Burden of disease among releasees in 1996, CDC, NIJ, Abt survey. CDC, Harold Margolis, Hepatitis Branch. 
**Hammet et al. noted an extreme lack of HBV data on correctional populations. These numbers are rough 
period prevalence estimates based on studies done in CA (1994) and NY (1987-1997) correctional systems.
***The total number of incarcerated persons in the US, numbering about 2 million, is composed of long-term pris-
oners, some with intermediate sentences of a few years only, and some held for a few days or weeks. This leads
in some cases to the same infected person being released several times a year, thus inflating the yearly number
of infected released persons. These considerations apply to HIV, HBV and HCV.
Dear Colleagues,
I am sure many of you are having as much difficulty focusing on the task at hand in the aftermath
of the Sept 11 terror as I am. Our world, as we knew it, changed forever on that day. Here at
HEPP News, our hearts go out to the families of the innocent victims of the attack. We also honor
the firefighters, police, rescue workers and volunteers for their selfless efforts. We need to be
inspired by them to focus and continue to carry out our duties. The goal of HEPP News is to pro-
vide our readers with up to date HIV and hepatitis information and the tools they need to carry
out their duties in the correctional health care setting. In the words of Mayor Guliani, the show
must go on. 
This issue of HEPP reviews communicable diseases in correctional settings, in preparation for
our symposium entitled Bridging the Gap scheduled for November 10 in Albuquerque, New
Mexico at the National Commission on Correctional Health Care (NCCHC) conference. We have
summarized recent reports of communicable disease outbreaks and recent data on the preva-
lence of communicable disease in correctional settings in the main article, and dedicated our
Spotlight feature to a study performed by Grace Macalino and colleagues in Rhode Island.  The
HEPPigram provides information on clinical flags that should prompt health care providers to
screen for HCV, HIV, and HBV in the correctional setting, and the HIV 101 provides information
on the signs and symptoms of acute HIV infection. 
Next month we will discuss recent studies on the immunotherapy of HIV and bring you updates
on new HIV drugs from recent conferences. In a future issue we will summarize CDC guidelines
for the diagnosis and treatment of hepatitis in correctional settings. The formalized guidelines are
expected to be released in late 2001 or early 2002.
CME credit is available both on line and by fax for readers of this issue. After reviewing this issue
of HEPP News, health care providers should be aware of the prevalence (and incidence) of com-
municable diseases in correctional settings, should be familiar with signs and symptoms of acute
HIV infection, and will recognize clinical flags that indicate the need to test for communicable
diseases. 
As always, we encourage you to write us and give us your feedback. Thank you for your contin-
uing efforts to improve correctional health care and willingness to address the task at hand.
Sincerely,
Anne De Groot, M.D.  
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4are included in the high-risk category) (22).
Again, limiting vaccination to higher-risk
inmates (those with a history of IDU, for
example) would lower costs (23).
STDs: Jail intake represents an important
opportunity for STD screening. However, the
rapid turnover of inmates can limit the effica-
cy of STD diagnosis and treatment. A num-
ber of rapid tests for STD infections have
been developed (24). In Chicago, these
methods for rapid STD diagnosis and treat-
ment led to the identification of most of the
city’s STD cases and successful treatment
before release (25,26).
EXISTING PROTOCOLS
Currently, different prisons have different
protocols on testing and treating communi-
cable diseases. One example of a protocol
addressing HCV comes from the
Pennsylvania Department of Corrections
(27). Inmates who are HCV  positive or
request an HCV test are also tested for HIV,
if at high risk. Those who are HCV positive
are educated about HAV and HBV vaccines,
and those who have more than 12 months
left on the minimum sentence and are not
excluded from treatment for other medical
reasons and are HIV negative are then
offered HCV treatment. If the inmate
accepts, the treatment proceeds. (See April
2001 HEPP News, available on line at
http://www.HIVcorrections.org, for a full dis-
cussion of HCV treatment protocols).
According to Dr. Fred Maue, MD, chief of
clinical services in the Pennsylvania DOC,
10,135 inmates there have been tested as of
May 31 2001, and 5,429 tested positive for
HCV infection. Of those, 292 have complet-
ed treatment and 378 are receiving treat-
ment. Of those not receiving treatment, 40%
are still under evaluation, some were exclud-
ed because of medical, psychiatric, drug and
alcohol abuse and sentencing reasons, and
20% refused treatment after having met the
criteria for receiving it (28). Every inmate has
received one-on-one education about HCV
with a trained healthcare provider.
New protocols for treating latent TB infection
were developed by the CDC and published
in June, 2000. Updated protocols reflecting
concerns about PZA/Rifampin toxicity (see
Newsflash in this issue) and guidelines for
appropriately identifying and treating latent
TB infection in correctional settings can be
obtained from the CDC Division of
Tuberculosis Elimination, at www.cdc.gov/
n c h s t p / t b / p u b s / m m w r h t m l / m m w r _
updates.htm (29). HIV treatment protocols
are revised by a committee of experts every
year: updated protocols available online
at the Health Resources and Services
Administration website, www.hab.hrsa.gov,
and at an AIDS Education website,
www.aegis.com.
EDUCATION, EDUCATION,
EDUCATION
Education is not only arguably the most
effective way to achieve prevention of trans-
mission, it is also one of the cheapest. A
study by the CDC published this year found
that HIV prevention programs in prison that
included testing and counseling not only
saved society a lot of money (while preven-
tion programs can seem expensive, treat-
ment after infection costs a lot more), it
reduced the risk of infection for uninfected
inmates by 20%, and transmission from
infected inmates by 25% (30). Another study
in San Francisco found that prerelease risk
reduction counseling reduced sex- and drug-
related risk behavior of inmates after release,
and improved the use of community
resources (31). Peer-led education has been
convincingly demonstrated to be the most
effective form of education for inmates.
Treatment and education programs may
need to be gender-specific, since female
prison populations often have different dis-
ease dynamics than their male counterparts.
For instance, about 10% of women who
enter jails in the US are pregnant. The pre-
vention of mother-to-child HIV transmission
is a particularly important intervention for cor-
rectional facilities. Infants of mothers with
acute (and chronic active) HBV infection are
also at risk of contracting the disease.
CONCLUSION
Because of the complex relationship
between various communicable diseases,
and the high prevalence of infection among
prison populations, effective management
programs have to be coordinated efforts that
screen for various risk-associated behaviors
and medical conditions. Prison and jail-
based programs, in the context of overall
public health interventions, are extremely
effective for the following reasons: they have
the potential of identifying and reaching a
high number of those infected with communi-
cable diseases and those at risk of infection,
and they effectively bring treatment and pre-
vention strategies directly to a population
that is at highest risk in a setting that may be
more conducive to learning than educational
programs located "on the street (32,33)."
Communicable diseases impact more than
the correctional population, as inmates
eventually return to their communities. Will
correctional facilities act as incubators or
educators? That is the question of the new
millennium.
*Nothing to disclose.
**Speakers Bureau: Merck & Co., Roche, and Schering-Plough
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Spotlight: Bloodborne Pathogens in RI: Is the greatest threat inside or out?
5
What is the risk of contracting a bloodborne disease while serving a
prison term?  How does this compare to the community risk? At the
Adult Correctional Institute (ACI) of Rhode Island, this question may
be first on the list of fears among any of the 15,000 people that pass
through ACI intake every year. Yet studies may show that the real
threat lies on the outside, which makes prisons and jails an essen-
tial intervention site for disease prevention in the free community.
Through cooperation with the medical department at the ACI, two
Brown University studies investigate the real risk of becoming
infected with bloodborne diseases behind closed doors.
Two Studies
Over the past three years, Macalino and her colleagues have con-
ducted a blind sero-survey of all sentenced inmates entering the
ACI. Blood is drawn at intake by the ACI for mandatory testing for
HIV. For the first part of the study, researchers send half of the
excess sera samples from sentenced inmates
to off-site laboratories to blind-test for Hepatitis
B and C (HBV and HCV) as well as Human T-
Lymphotropic Virus (HTLV I/II).
The other half of the sera samples are reserved
(linked with demographic data) for the second
part of the study, or incidence measurement.
This part requires new blood samples from
inmates who have continuously been at the ACI
for a minimum of 11 months. Macalino chose
this timeframe to account for those individuals
who might have been in the seroconversion
window.   At 11 months, eligible inmates are
consented, pre-test counseled, and a phle-
botomist draws blood from these volunteers.
The blood is tested for HBV, HCV, and HTLV I/II
infection. Outreach workers return within a month to counsel and
disclose test results.
This study has been highly successful, accepted both among
inmates (consent rate of 78%) as well as the administration at the
ACI.  According to Macalino, study participants may be more recep-
tive to her study because the outreach workers are not affiliated with
the correctional administration.  
Because the first part of the study is a blinded sero-survey, all sen-
tenced inmates are tested, resulting in an unbiased sample.
However, because the second part of the study requires consent, it
is possible that the inmate sample is biased.  Additionally, the
results from this study can only be extrapolated to those who are
incarcerated for at least 11 months, leaving questions about trans-
mission of these infections in more transient correctional popula-
tions still unanswered.  
In a second study, Macalino and colleagues are measuring preva-
lence of the same bloodborne pathogens among recidivist men. The
design is similar to an earlier study conducted with women inmates
at the ACI (Rich JD, Macalino GE, Dickinson B, Flanigan T. CDC
HIV Prevention Conference: Community incidence and intake
prevalence in a population of incarcerated women. Atlanta, GA,
August, 1999).  Macalinos recidivist study will estimate "communi-
ty" incidence of these infections by comparing the results of serial
samples obtained at intake. Since inmates are often in the correc-
tional system for short periods of time, Macalino attributes this     
incidence (i.e., negative on an earlier intake and positive on a later
intake) to transmission in the community.
The Numbers
The incidence and seroprevalence study
Ultimately, Macalino hopes her data will reveal the transmission rate
of HIV, HBV, HCV and HTLV I/II within the prison.  Her preliminary
results from the 675 participants at intake found prevalence rates of
1.3% HIV, 19.8% HBV, 24.7% HCV, and 1.2% HTLV I/II.  Preliminary
analysis found no seroconversion to reveal infection with HIV, HCV
or HTLV I/II.  They did find, however, two cases of conversion to
HBV infection, although further tests are necessary to confirm this
finding. 
Macalino and colleagues also noted injection drug use (IDU) among
study participants, and found the highest rate of IDU among those
patients infected with HIV: 66.7% (6) reported drug
use.  For those with HBV, IDU was 38% (51); for
HTLV I/II, 50% (4); and for HCV, 46% (78).  
The recidivist study
In the study of recidivist women at the ACI (Rich, et
al), 2.4% (25) returned from the community infected
with HIV. The numbers are much higher for
Hepatitis:  34% (140) had HBV, and 36% (150) had
HCV. Nine women (2.2%) had HTLV I/II.
Extrapolating to measure in person-years, the study
found that HCV had the highest rate community inci-
dence (18.2/100 person-years), followed by HBV
(12.2/100 person-years), HTLV II (0.9/100 person-
years) and HIV (0.31/100 person-years).  
Because of these results, colleagues of Macalino
recently received a grant to evaluate the feasibility of Hep B vac-
cines in prison. The recidivist study for this project is still in progress
and no results exist yet. The project will eventually have communi-
ty incidence data for both the men’s and women’s  facilities.
Hopeful for an Impact
Macalino anticipates that transmission rate within the prison will be
much less than on the outside.  Still, any positive results will indicate
to the ACI administration that education and prevention should be
an essential component of their staff training and inmate health-edu-
cation programs. These studies can provide information on whether
funding and educational efforts should be directed at inmates during
incarceration or upon release. Macalino said that ACI Medical
Director Anne Spaulding has been very receptive to the study, stat-
ing that it is better to know than not to know the transmission rates
within the prison.  
Revealing a common sentiment about research in hard to reach
populations, Macalino said My frustration is that you hope that
youre going to make change [but it is not a guarantee].  This is a
high risk populationa hidden population.  They  are not going to
be in most studies or accessing care, and there is chronic history of
feeling overlooked and mutual distrust.  She is optimistic, however,
stating that research is possible within corrections, provided that
researchers establish open communication and awareness among
all interested or involved staff and inmates.
HEPP News writer Betsy Stubblefield* interviewed Grace Macalino, PhD, Assistant Professor at the Brown 
University Department of Community Health
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Research is possible
within corrections, 
provided that
researchers establish
open communication
and awareness among
all interested or
involved staff 
and inmates.
*Nothing to disclose.
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Type of Visit and Finding
Testing & Education Recommended
HBV                    HCV                   HIV
GYNECOLOGICAL
G STDs (include Herpes, Syphilis, etc.)
G Trichomonas vaginalis 
G Vaginal Yeast Infection 
G History of Childhood Sexual Abuse1, 2
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G Schizophrenia3
G Bipolar Disorder3
G Post-Traumatic Stress Disorder
G History of Childhood Sexual Abuse
G IV Track marks
G Icterus
G Signs of acute HIV (see HIV 101)
G Signs of chronic HIV (including thrush, scars 
from shingles, OHL, lymphadenopathy, seborrhea)
G Positive TB test
G Hepatitis Infection (A or B)
G Hepatitis Infection (A or C)
G Shingles
G Seborrheic dermatitis
G Abnormal LFTs
G Severe fungal infection
G Uncontrollable psoriasis
Level or strength of recommendation: +++ High recommendation; ++ Medium recommendation (suggesting indirect link between
finding and diagnosis); + Low recommendation. Developed by HIV and Hepatitis Education Prison Project (HEPP News) Staff,
September 2001.
Inmates may present with any of the above symptoms at any time during their incarceration, not only at intake.  There may be
inmates who are infected with HIV, HBV, or HCV at the time of intake but have not yet seroconverted resulting in a negative testing
outcome when they are actually infected with one or more of these viruses.  Additionally, there are inmates who acquire these virus-
es while incarcerated and thus will exhibit these symptoms at a medical visit post-intake.
REFERENCES:
1. Cohen M, Deamant C, Barkan S, et al. Am J Public Health. 2000 Apr;90(4):560-565
2. Bensley LS, Van Eenwyk J, Simmons KW Am J Prev Med. 2000 Feb;18(2):151-158
3. Otto-Salaj LL, Stevenson LY The AIDS Reader. 2001 Apr; 11(4): 197-208
MENTAL HEALTH
GENERAL HEALTH
7The diagnosis of acute HIV infection is missed approximate-
ly 75% of the time because of a low level of suspicion of HIV
on the part of the provider (1). 
GAcute HIV infection is often mistaken for another disease or
for a minor, passing illness. 
G Signs and symptoms of acute HIV infection mimic those of
mononucleosis, influenza, viral hepatitis, or secondary
syphilis (1,2). 
G 50 to 90% of patients experience symptoms of the acute
infection syndrome, which usually develops 2 to 4 weeks after
initial exposure to the virus (2). 
G Patients most commonly present with the following signs
and symptoms: fever, fatigue, lymphadenopathy, pharyngitis,
rash, and weight loss. Mylagia, arthralgia, and headache are
also reported by patients experiencing acute HIV infection
(see Table 1). 
G The skin rash that appears during acute HIV infection usu-
ally affects the trunk or face in a symmetric distribution and is
described as an erythematous, nonpruritic, maculopapular
eruption (2). Ulcerations may occur, especially in the oral and
genital areas (2). 
A patient who exhibits some or all of the signs and symptoms
listed in Table 1 and exhibits recent risk for HIV infection
should be tested for HIV infection. The duration of the symp-
toms is approximately 14 days after which time the immune
system begins producing antibodies to the virus, the viral load
in the body decreases and the symptoms are often resolved
(3). The duration and severity of acute HIV infection is often
a prediction of disease progression. Symptoms that are more
severe and prolonged correlate with rapid disease progres-
sion (1, 3).
Blood tests commonly reveal an initial lymphopenia with
depletion of CD4+ and CD8+ cells. This is a short-lived phe-
nomenon followed by lymphocytosis (largely CD8+ cells),
anemia, and thrombocytopenia (2). Hepatic transaminases
and alkaline phosphatase levels are also associated with 
acute HIV infection but generally return to normal within three
months (2). If the levels do not return to normal in this time, it
may be a sign of co-infection with one of the hepatitis viruses
(i.e. HBV, HCV).
Recognizing the signs of acute HIV infection is necessary to
diagnose HIV infection and begin treatment. Traditional HIV
tests depend on the presence of serum antibodies to proteins
of the HIV virion. However, these antibodies often do not
develop until after the symptomatic acute stage of HIV has
passed. Direct detection of HIV RNA or DNA is the most rapid
diagnostic test. 
Treating HIV with antiretroviral therapy in the acute stage is
extremely beneficial to the patient (1,2,3). Treatment can
reduce viral replication, lowering the viral load and reducing
the emergence of drug resistant HIV phenotypes (1). Patients
who receive antiretroviral therapy during the acute stage of
infection have experienced a rise in CD4+ and CD8+ cells to
normal levels and the reduction of viral load to undetectable
levels (2).
^Nothing to disclose.
*Adapted from:
1. Perlmutter, BL, Glaser, JB, and Oyugi, SO. How to recognize and treat acute HIV syndrome. Am Fam Physician 1999 Aug; 60 (2):535-42.
2. Vergis, EN and Mellors, JW. Natural history of HIV-1 infection. Infect Dis Clin North Am 2000 Dec; 14 (4):809-25.
3. Kahn, JO, and Walker, BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998 Jul 2; (1):33-9.
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1 Dont Miss the Diagnosis (HIV)*
Table 1. Frequency of Signs and Symptoms
Associated with Acute HIV Infection (1, 2)
Sign/Symptom
G Fever
G Fatigue
G Rash
G Lymphadenopathy
G Weight Loss
G Pharyngitis
G Headache
G Mylagia or Arthralgia
G Nausea, Vomiting, 
or Diarrhea
% Patients 
Reporting Symptom
90
80 to 90
40 to 80
40 to 77
70
50 to 73
32 to 70
50 to 70
30 to 60
Rebecca Nerenberg^, HEPP News Staff Writer
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Resources & Websites
Acute HIV Websites:
AIEDRP: Acute HIV Infection and Early Disease Research
Program
http://aiedrp.fhcrc.org/
IAPAC (International Association of Physicians in AIDS Care)
Guidelines for Acute HIV Infection
http://www.iapac.org/guidelines/guidelines14.html
HIV ATIS Guidelines for Acute HIV Infection
http://www.hivatis.org/guidelines/adult/Apr23_01/text/acute.html
Hepatitis Packets Available:
NATAP: 15-page handbook on HCV and HIV/HCV Co-infection. Also
available in Spanish. Contact JuLev@aol.com 
Hepatitis C Awareness Project: 14-page packet on HCV targeted
for and available to inmates and others. Contact pkbeckinor@aol.com
HIV Treatment Websites:
CARE Act Guidelines
http://hab.hrsa.gov/care.html
HIV and Hepatitis
http://www.hivandhepatitis.com/
amfAR Treatment Directory
http://www.amfar.org/cgi-bin/iowa/td/
CDC HIV/AIDS Treatment Information
http://www.cdc.gov/hiv/treatment.htm
The Body: An AIDS and HIV information resource
http://www.thebody.com
Rainbow/PUSH Coalition Website
http://www.rainbowpush.org
Management of HIV/AIDS in the
Correctional Setting: A Live
Satellite Videoconference Series
Antiretroviral Therapy: Charting a
Successful Course
October 16, 2001 
12:30-3:30pm EST
Sponsored by the Albany Medical
Center’s AIDS Program
CME and CEU credits available
Call: 518.262.4674
Email: rosentjh@mail.amc.edu
Visit: www.amc.edu/Patient/
HIV/hivconf.htm 
Focus on Women: Challenges in
the Prevention and Treatment of
HIV/AIDS
Sponsored by AmFar
October 19, 2001
Cornell Club, New York, New York
Fee: $35
Call: 212.806.1627
Email: caroline.kelley@amfar.org
Infectious Diseases Society of
America (IDSA): 39th Annual
Meeting
Oct 25-28, 2001
San Fransisco, California
Email: sharwood@idsociety.org
Write: 99 Canal Center Plaza,
Suite 210 Alexandria, VA 22314
Fax: 703.299.0204
Visit: http://www.idsociety,org
National Conference on
Correctional Health Care
November 10-14, 2001
Alberquerque, New Mexico
Fee: Before Oct 1- $225 member/
$275 non-member; 
after Oct 1- $275 member; 
$325 non-member
Call: 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org 
3rd International Hepatitis C:
Update for the New Millennium
November 30-December 1, 2001
Houston, Texas
Fee: Physicians- 
before Oct. 29- $150; 
after Oct. 29-$165; 
Other Health Care Professionals-
before Oct. 29- $115; 
after Oct. 29-$135
Visit: http://www.uth.tmc.edu/cme/
Email: Kristen.K.Brockman@
uth.tmc.edu 
Call: 713.500.5127
CME and CEU credit available
Save the 
Dates
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Drug Resistant HIV on the Rise
Nat Med 2001 Sep; 7(9):1016-1020
By 2005 experts expect 42% of individuals living
with HIV will be infected with drug-resistant
strains of the virus, according to a mathematical
model. The percentage of individuals with drug-
resistant virus rose from none in 1996 (pre-pro-
tease inhibitors) to 28.5% in 1999. Experts say
that the majority of new drug resistant cases are
drug-acquired rather than sexually transmitted.
Scientists are hoping that new drugs in develop-
ment will combat the drug-resistant viruses.
Revisions in CDC Guidelines for the
Treatment of Latent Tuberculosis Infection
MMWR 2001 August 31; 50(34):733-35
After more than 20 cases of severe liver injury
associated with a 2 month rifampin-pyrazi-
namide (RIF-PZA) regimen for the treatment of
latent tuberculosis infection (LTBI), the CDC has
issued revised recommendations. The 2-month
RIF-PZA treatment regimen is to be used with
caution, especially for patients taking other med-
ications associated with liver damage and is not
recommended for people with alcoholism. For
HIV-negative patients, 9 months of daily INH is
the preferred form of treatment. Full guidelines
available at http://www.cdc.gov/mmwr/PDF/
wk/mm5034.pdf.
Roche Releases a New CMV Drug
In March, the FDA approved a new drug,
Valcyte, manufactured by Roche to combat
cytomegalovirus (CMV), a common opportunis-
tic infection in HIV-positive patients. Valcyte (val-
ganciclovir HCl tablets) is a 450mg tablet for oral
administration. Valcyte is the only drug with oral
administration in induction therapy and can be
given once daily. The side effect profile is similar
to Cytovene.
Ryan White CARE Act Funds for Discharge
Planning
HRSA AIDS Bureau, August 2001
As of July 2001, HRSA AIDS Bureau (HAB)
released a program policy that outlines the use
of Ryan White CARE Act funds for use in the
discharge planning of inmates. The purpose of
the funding is to provide transitional primary
care for inmates nearing release linking primary
care within prisons to primary care in the com-
munity. This funding provides services not cov-
ered by the correctional system. The policy is
available on the HAB website at http://hab.hrsa.
gov/care.html.
Abnormal Cervical Cytology in HIV+ Women
J Acquir Immune Defic Syndr 2001 Aug 15; 27
(5): 4232-442
Scientists released a new study comparing the
incidence, progression and regression rates for
abnormal cervical cytology between HIV-posi-
tive and HIV-negative women. HIV-positive
women were found to be at high risk for abnor-
mal cytology with HIV status and HIV RNA level
predicting the incidence of the abnormalities.
Hepatitis B Transmission Observed in
Correctional Facilities
MMWR 2001 Jun 29; 50(25):529-32
Acute hepatitis B was serologically confirmed in
a male (index patient) who had been incarcerat-
ed at a high security state correctional facility for
2.5 years. His only reported risk for infection
was unprotected sex with his cellmate.
Serologic testing revealed that the cellmate had
chronic hepatitis B virus (HBV) infection yet the
inmate was previously unaware of his condition.
Additional cases of HBV infection were found in
this facility underscoring the need for HBV vac-
cination in prisons and jails.
Hepatitis C Treatment in Prisons
Associated Press, September 4, 2001
Over 18% of inmates are infected with hepatitis
C, an incidence rate of over ten times that of the
general population. Testing for hepatitis C in
prisons not common, however, due to prohibitive
treatment costs ($14,000 per patient per year)
and the time required for treatment success (up
to 18 months). Because many inmates will or
may be released in less than 18 months, they
are often not treated for hepatitis C. Of over 800
infected inmates in New Jersey, only 10 are in
treatment. The majority were turned down
because of insufficient time left on their sen-
tences to complete treatment.
Experimental HIV Drug Effective in 
Drug-Resistant Patients
Reuters, 9/26
Tenofovir, an experimental antiretroviral drug
now under consideration for approval by the
FDA, was tested for six months in patients with
drug-resistant viruses.  A "more significant
reduction" in HIV viral load was seen when
patients were treated with tenofovir in combina-
tion with other antiretroviral medications rather
than with a placebo used in conjunction with
other antiretrovirals.
News Flashes
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Bridging the Gap: Meet HEPP News
Meet HEPP News! Editors Bick, Paar, Paris,
and De Groot will be speaking at a precon-
ference symposium on Saturday November
10, 2001 from 1:30-5:00pm at the National
Conference on Correctional Health Care in
Albuquerque, New Mexico. Additional speak-
ers include Dr. Renee Kanan, Dr. Michael
Wong, Dr. Rob Lyerla and others.The focus
of this symposium is on Bridging the Gap:
Getting High Risk Patients into Treatment
and will address the issues surrounding the
gap between those inmates who have an
infectious disease and those who are active-
ly receiving treatment. CME credit will be
available. Information on the conference is
available at http://www.ncchc.org.
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through December 31, 2001. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. What is the correct order of community incidence rates in
Rhode Island from highest to lowest, according to the Macalino
study?
(a) HCV>HIV>HBV>HTLV II
(b) HCV>HBV>HTLV II>HIV
(c) HBV>HCV>HIV>HTLV II
(d) HIV>HBV>HTLV II>HCV
(e) HIV>HTLV II>HCV>HBV
2. Which of the following conditions was estimated to be the most
prevalent in prisons in 1999?
(a) chlamydia
(b) gonorrhea
(c) syphilis (RPR+)
(d) herpes (active)
(e) genital warts
3. Approximately how long after initial exposure to HIV do the
symptoms of acute infection develop?
(a) seven to ten days
(b) two to four weeks
(c) six to eight months
(d) three to five days
(e) two to four months
4. Why is an anti-HIV antibody test inappropriate to use in 
diagnosing acute HIV?
(a) antibodies may not appear until after symptomatic acute 
infection has passed
(b) anti-HIV antibodies are non-specific
(c) the test is too expensive 
(d) patients with fever can not expect accurate test results
(e) anti-HIV antibodies do not indicate active virus
5. Under what conditions should the RIF-PZA treatment for HIV-
positive people with latent tuberculosis infection (LTBI) not be
used?
(a) when the patient is on acyclovir
(b) when the patient is co-infected with hepatitis B virus
(c) when the patients does not like the side effects
(d) when the patient has a history of alcoholism
(e) all of the above
6. A patient arrives in your general outpatient  clinic complaining
of a painful rash.  He has a maculopapular rash on the right side
of his chest. You think it is shingles. What will you screen for?
(a) HIV
(b) HBV
(c) lyme disease
(d) measles
(e) drug reaction
BROWN MEDICAL SCHOOL   OFFICE OF CONTINUING MEDICAL EDUCATION   BOX G-A2    PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HIV 101 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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